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A B S T R A C T
Human female fetal reproductive tracts 9.5–22 weeks of gestation were grown for 1 month in ovariectomized
athymic adult female mouse hosts that were either untreated or treated continuously with diethylstilbestrol
(DES) via subcutaneous pellet. Normal morphogenesis and normal patterns of differentiation marker
expression (KRT6, KRT7, KRT8, KRT10, KRT14, KRT19, ESR1, PGR, TP63, RUNX1, ISL1, HOXA11 and α-
ACT2) were observed in xenografts grown in untreated hosts and mimicked observations of previously reported
(Cunha et al., 2017) non-grafted specimens of comparable age. DES elicited several notable morphological
affects: (a) induction of endometrial/cervical glands, (b) increased plication (folding) of tubal epithelium, (c)
stratified squamous maturation of vaginal epithelium and (d) vaginal adenosis. DES also induced ESR1 in
epithelia of the uterine corpus, cervix and globally induced PGR in most cells of the developing human female
reproductive tract. Keratin expression (KRT6, KRT7, KRT8, KRT14 and KRT19) was minimally affected by
DES. Simple columnar adenotic epithelium was devoid of TP63 and RUNX1, while DES-induced mature vaginal
epithelium was positive for both transcription factors. Another striking effect of DES was observed in grafts of
human uterine tube, in which DES perturbed smooth muscle patterning. These results define for the first time
IHC protein markers of DES action on the developing human reproductive tract, which provide bio-endpoints of
estrogen-induced teratogenesis in the developing human female reproductive tract for future testing of
estrogenic endocrine disruptors.
1. Introduction
The tacit, but unproven assumption inherent in the use of animal
models, is that they are representative of human biology, even though
substantial differences exist between human versus animal anatomy,
development and pathology. One field for which animal/human
pathology is particularly congruent concerns the effects of exogenous
estrogens on the developing female reproductive tract. Administration
of diethylstilbestrol (DES) to pregnant women from the 1940s to the
1970s resulted in a broad spectrum of estrogen-induced malformations
of the uterine tubes, uterine corpus, cervix and vagina that include T-
shaped uterotubal junctions, malformed incompetent cervix, abnor-
mally shaped endometrial cavity, vaginal adenosis (presence of gland-
ular epithelium in the vagina where normally stratified squamous
epithelium should reside) and clear cell vaginal adenocarcinoma
(Jefferies et al., 1984; Rennell, 1979; Stillman, 1982; Titus-Ernstoff
et al., 2010; Herbst et al., 1971, 1975b; Robboy et al., 1977, 1984;
Hoover et al., 2011). An immense animal literature preceded/con-
firmed the effects of exogenous estrogens on female reproductive tract
development, and animal studies have provided a molecular under-
pinning for the teratogenic effects of natural estrogens (17β-estradiol
(Forsberg, 1972), 17α-estradiol (Forsberg and Kalland, 1981), estra-
diol benzoate and synthetic estrogens (diethylstilbestrol (McLachlan,
1981), dienestrol (Forsberg and Kalland, 1981), clomiphene citrate
(Gorwill et al., 1982), tamoxifen (Taguchi and Nishizuka, 1985),
nafoxidine (Iguchi et al., 1986), coumestrol (Burroughs et al., 1990)
and bisphenol A (BPA) (Newbold et al., 2009) on urogenital develop-
ment (Herbst and Bern, 1981; Bern and Talamantes, 1981; Bern et al.,
1984; McLachlan et al., 1975, 2001; McLachlan, 1981; Newbold et al.,
1983; Newbold and MaLachlan, 1985; Newbold, 1995, 2004, 2008;
McLachlan and Newbold, 1996; Kurita et al., 2004; Kurita, 2011;
Laronda et al., 2012, 2013). The animal literature on this topic is
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replete with observations of vaginal, cervical, uterine and tubal
(oviductal) anomalies including cervicovaginal adenosis. While animal
models have been useful and relevant to many aspects of human
biology/pathology, animal studies frequently are the basis of govern-
mental policy designed to protect human health. Accordingly, when-
ever possible it is important to establish by experimental means the
congruence (or lack thereof) of animal studies to human biology/
pathology.
Despite the mouse/human similarities in estrogen-induced anoma-
lies in the female reproductive tract, the molecular mechanisms leading
to human malformations are poorly understood even though mouse
studies provide some clues (McLachlan and Newbold, 1996; Kurita
et al., 2004; Kurita, 2011; Laronda et al., 2012, 2013). Direct
experimentation on human fetal xenografts treated with DES can
provide important insights into the genesis of human malformations
and can provide essential bio-endpoints of hormonally active endocrine
disruptors with direct relevance to human development. In this regard,
we pioneered xenograft methods about 35 years ago in which human
fetal female reproductive tracts were grown in athymic mouse hosts
treated with DES and other hormonally active agents (Cunha et al.,
1987b, 1987a; Robboy et al., 1982; Taguchi et al., 1983). However, the
then existing state of technology prevented further exploration of
molecular mechanisms. In the current paper we analyze an entirely
new set of specimens to (a) revisit our xenograft model of human
female fetal reproductive tract development, (b) provide new data to
validate normal development in xenografts to untreated hosts and (c)
explore the how DES exposure affects the morphogenesis, differentia-
tion and molecular expression within human female fetal reproductive
tracts. Our resultant studies provide the essential underpinning for
future studies of human female reproductive tract development
designed to explore the mechanism of mesenchymal-epithelial inter-
actions in epithelial morphogenesis, differentiation and gene expres-
sion, and especially the role of direct versus paracrine signaling in the
expression of human uterine epithelial ESR1 and PGR.
2. Materials and methods
2.1. General comments
First and second trimester human fetal specimens devoid of patient
identifiers were collected from 2015 to 2017 after elective termination
of pregnancy (Committee on Human Research, IRB# 12-08813). Fetal
age was estimated using heel-toe length (Drey et al., 2005). Gender was
determined by virtue of Wolffian and Müllerian duct morphology.
Female internal genitalia were identified and isolated from the abortus
specimen using a dissecting microscope. This study is based upon 5
control specimens grafted into untreated hosts and 5 specimens grafted
into DES-treated hosts collected over the period of 2015–2017
(Table 1). The control group consisted of 4 grafts of intact reproductive
tracts (11–14 weeks of gestation) as well as 1 additional specimen at 15
weeks of uterine tube only. The DES-treated group consisted of 4 intact
specimens at 9.5 and 14 weeks of gestation and one additional
specimen of uterine tube only at 22 weeks. The term “intact” means
that the specimen contained uterine tubes and the uterovaginal canal.
In some cases the lower portion of the uterovaginal canal (the
urogenital sinus component) may have been missing, even though
the rudiments of the uterine tube, uterine corpus, uterine cervix and
vagina were present in all of the “intact” specimens. The uterine tube
only specimens (AC297 and AC316) were divided into multiple
individual grafts. Since the data from these tube only grafts did not
vary, they are registered as a single graft. Fortuitously, the intact 13-
week specimens were twins, which provided the most ideal means of
comparison between control and DES treatment. Most of the images in
this paper were taken from the 13- and 14-week specimens.
Immunostaining results within the 5 control specimens were remark-
ably consistent. DES treatment elicited a distinctly different immunos-
taining profile that was remarkably similar within this treatment group.
The additional specimens of “uterine tube only” were used primarily for
examination of α-actin immunostaining.
2.2. Grafting of human fetal female reproductive tract organs
For the younger specimens (9.5–14 weeks of gestation) the entire
human female reproductive tract with attached uterine tubes was
grafted under renal capsules of ovariectomized female athymic mice
(Charles River, Hollister, CA) as described previously (Cunha and
Baskin, 2016). Our xenograft model differs in many respects from
human in utero development (absence of a human maternal uterus,
liver and absence of the placenta). Therefore, at the onset of this study
we considered whether to use ovary-intact or ovariectomized hosts.
Both approaches have merit. Use of ovariectomized hosts has the
advantage of being able to discern effects of DES independent of other
hormonal variables, and thus we chose this condition. DES is known to
have far reaching systemic hormonal effects when administered to
pregnant or neonatal mice, and presumably also had comparable
effects on historic human pregnancies, which cannot be replicated in
the xenograft model. Whether the use of ovary-intact hosts may give
different results remains to be determined in future studies. Host mice
were ovariectomized and either untreated or implanted subcutaneously
with a 20 mg DES pellet. After 4 weeks of in vivo growth the grafts were
harvested for analysis. The effectiveness of the ovariectomy in un-
treated hosts was determined by examination of hosts’ uteri, which in
all cases were atrophic. Likewise, the effectiveness the DES pellet was
verified by hypertrophy of the hosts’ uteri (not illustrated).
2.3. Histologic and immunohistochemical (IHC) analysis
At harvest, grafts of human fetal female reproductive tracts were
dissected from the kidney, fixed for at least 24 h in 10% buffered
formalin, embedded in paraffin and serially sectioned at 7 microns.
Every 20th section was stained with hematoxylin and eosin (H& E).
The remaining paraffin sections were immunostained with the anti-
bodies indicated (Table 2). Immunostaining was detected using horse-
radish peroxidase based Vectastain kits (Vector Laboratories,
Burlingame, CA). Negative controls deleted the primary antibody.
Table 1
Grafts of human female fetal reproductive tract specimens.
Specimen # Treatment Age Intact versus tube only
AC115 Control 11 weeks Intact
AC514 Control 11 weeks Intact
AC121* Control 13 weeks Intact
AC159 Control 14 weeks Intact
AC297 Control 15 weeks Tube only
AC509 DES 9.5 weeks Intact
AC513 DES 10.5 weeks Intact
AC122* DES 13 weeks Intact
AC159 DES 14 weeks Intact
AC316 DES 22 weeks Tube only
Control = Untreated ovariectomized host.
DES = DES-treated ovariectomized host.
* AC121 (Control) and AC122 (DES) are from a twin pregnancy.
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3. Results
3.1. Epithelial and mesenchymal differentiation in grafts of human
fetal female reproductive tracts grown in untreated ovariectomized
female hosts
3.1.1. General comments
Xenografts implanted into untreated ovariectomized hosts were
derived from fetuses 11-15 weeks of gestation. In an earlier report
(Cunha et al., 2017) we studied the expression of epithelial and
mesenchymal differentiation markers in developing human fetal female
reproductive tracts over the time frame of 8–21 weeks. Prior to 11 weeks
of gestation in non-grafted specimens, many markers are weakly ex-
pressed, while at later stages epithelial and mesenchymal differentiation
markers are strongly expressed (Cunha et al., 2017). Accordingly, our
xenograft experiments using specimens in the age range of 11–15 weeks)
Table 2
Antibodies used in this study.
Antibody # Source Catalogue # Dilution
Keratin 6 Acris Antibodies AM21068PU-S 1/200
Keratin 7 EB Lane LP1K 1/10
Keratin 8 EB Lane LE41 1/10
Keratin 10 Dako M7002 1/50
Keratin 14 BioGenex LL002 1/100
Keratin 19 EB Lane LP2K 1/100
HOXa11 Sigma HPA035623 1/400
TP63 Santa Cruz Biotechnology Sc-8343 1/100
ISL1 Abcam Ab20670 1/200
ESR1 Dako Ab16660 1/100
PGR Abcam Ab16661 1/100
RUNX1 Abcam Ab92336 1/100
alpha-ACT2 Sigma A-2547 1/3000
Fig. 1. MKi67 immunostaining in 13-week intact female fetal reproductive tract
(AC121) grown for 4 weeks in an untreated ovariectomized female athymic mouse host.
The developing uterine tube (A), vaginal plate (B) and uterus (C) all exhibit considerable
numbers of proliferating MKi67-reactive epithelial and mesenchymal cells. Scale bar in
(A) also applies to (B).
Table 3
Differentiation markers in non-grafted, untreated xenografts and diethylstilbestrol-
treated human fetal uterine tube.
Non-
grafted*
Grafted control-
No treatment
Grafted–DES Control/DES
figures
Epithelium
KRT7/8 +++ + (3/3) + (4/4) 4A/13D
KRT19 + + (2/2) + (4/4) NS/14A
KRT6 - - (2/2) - (4/4) NS/15A
KRT14 - - (2/2) - (4/4) 7A/16A
KRT10 - - (2/2) - (4/4) NS/NS
RUNX1 - - (2/2) - (4/4) 9D/18A
TP63 - - (2/2) - (4/4) 8C/17A
ESR1 +++ + (3/3) +/- (4/4) 3B/11A-B
PGR - - (3/3) + (4/4) NS/12A
Mesenchyme
α-actin + + (3/3) + (2/2) 20A/20B
ISL - - (3/3) - (3/3) 10A/NS
HOXA11 - - (3/3) - (3/3) 10B/19B
ESR1 + + (3/3) + (4/4) 3A-C/11B
PGR - - (3/3) + (4/4) NS/12A
NS = Not shown.
+/- = Patchy mixture of positive and negative cells.
* From Cunha et al. (2017).
Table 4
Differentiation markers in non-grafted, untreated xenografts and diethylstilbestrol-
treated human fetal uterus.
Non-
grafted*
Grafted control-No
treatment
Grafted–
DES
Control/DES
figures
Epithelium
KRT7/8 + + (3/3) + (4/4) 4A, B, D/
13A, C
KRT19 + + (3/3) + (2/2) 5A-B/14A
KRT6 - - (2/2) -/+ (3/4), -
(1/1)
6A-B/15A
KRT14 - - (3/3) - (4/4) 7A/16A
KRT10 - - (3/3) - (3/3) NS /NS
RUNX1 - + (3/3) +/- (4/4) 9A-B, D/18A,
C
TP63 - +/- (2/3) - (4/4) 8C/17A, D
- (1/1)
ESR1 + + (1/1) UGS + (3/3) 3C/11B-C
- (2/2) MD
PGR - - (3/3) + (4/4) NS/12A
AR + - (2/2) + (2/2)
Mesenchyme
α-actin + + (3/3) + (2/2) NS/NS
ISL - - (2/2) - (2/2) 10A/NS
HOXA11 - + (2/2) + (2/2) 10B/19B
ESR1 + + (3/3) + (3/3) 3A-C/11B-C
PGR - - (3/3) + (4/4) NS/12A
AR + (1/2) + (1/2) NS/NS
NS = Not shown.
UGS = Urogenital sinus-derived vaginal epithelium.
MD = Müllerian-derived vaginal epithelium.
* From Cunha et al. (2017).
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are ideal to assess the effects of DES on expression of protein differentia-
tion markers. Histologic sections of control specimens revealed continued
normal development of all organs (uterine tube, uterine corpus, uterine
cervix and vaginal plate/vagina) in the untreated xenografts, thus
corroborating our earlier xenograft studies (Cunha et al., 1987b, 1987a;
Robboy et al., 1982; Taguchi et al., 1983). Health of the xenografts was
verified by prominent MKi67 labeling in both epithelia and mesenchyma
in all grafts (Fig. 1). Finally, as indicated in our earlier report (Robboy
et al., 2017), boundaries between the uterine corpus, uterine cervix and
vagina are indistinct and so stated as “presumed” boundaries. Tables 3–5
summarize immunostaining results from non-grafted specimens from
Cunha et al. (2017) as well as from untreated and DES-treated xenografts
for the uterine tube (Table 3), the uterine corpus (Table 4) and the vagina
(Table 5). Results for the cervix are difficult to accurately assess due to the
indistinct boundaries between the uterine corpus, cervix and vagina.
Qualified cervical results are given in text only.
3.1.2. Sex steroid receptors
3.1.2.1. Estrogen receptor alpha (ESR1). In grafts of human female fetal
reproductive tracts grown in untreated ovariectomized hosts, ESR1 was
strongly expressed in the simple columnar epithelium of the uterine tube
(Fig. 2A-B) but not in epithelium of the uterine corpus or cervix (Fig. 2B-C
and Table 3–5), thus corroborating the pattern of ESR1 expression
observed in non-grafted specimens of comparable age (see the
accompanying paper) (Cunha et al., 2017). In the case of the vagina
there are two types of stratified vaginal epithelium derived from the
urogenital sinus (UGS) and the Müllerian ducts (uterovaginal canal),
respectively. The UGS-derived vaginal epithelium is located caudally in the
female reproductive tract, whereas the Müllerian-derived vaginal
epithelium is located cranially. Each has a distinctive morphology. In
grafts grown in untreated ovariectomized hosts, the UGS-derived vaginal
epithelium is organized into irregular solid FOXA1-positive cords (Robboy
et al., 2017), which are ESR1-positive (Fig. 2A, inset) (Table 5). The
Müllerian-derived vaginal epithelium is 3–4 cell layers in thickness, lines a
lumen, is PAX2-positive (Robboy et al., 2017) and is ESR1-negative (not
illustrated). ESR1 was expressed in mesenchymal cells associated with the
uterine tube, uterine corpus, and uterine cervix, although in the xenografts
grown in untreated ovariectomized hosts, a subset of the mesenchymal
cells was ESR1-negative (Fig. 2). ESR1-positive mesenchymal cells were
rarely seen in the developing vagina (Fig. 2A).
Table 5
Differentiation markers in non-grafted, untreated xenografts and diethylstilbestrol-
treated human fetal vagina.
Non-
grafted*
Grafted
control-No
treatment
Grafted-
DES
Strat. Epi.
Grafted-
DES
Adenosis
Control/
DES
figures
Epithelium
KRT7/8 + + (4/4) + (3/4) + (2/2) 4A-C, F/
13A-B
KRT19 + + (4/4) + (4/4) + (2/2) 5A, C/
14A-B
KRT6 + + (4/4) + (4/4) - (2/2) 6D/15A-
B
KRT14 - - (3/4) + (2/4) - (2/2) 7A-B/
16A-B+ (1/1)
KRT10 - - (4/4) - (4/4) - (2/2) NS/NS
RUNX1 - + (4/4) + (4/4) - (2/2) 9B, F/
18A-B
TP63 - + (4/4) + (4/4) - (2/2) 8D-E/
17A-C
ESR1 + - (3/4) MD + (3/4) + (2/2) 3A/11D
+ (1/1)
UGS
PGR - - (4/4) + (4/4) + (2/2) NS/12B
AR + - (4/4), - (4/4) + (2/2)
Mesenchyme
□-actin + + (3/3) + (4/4) + (2/2) 20A/20B
ISL - +(2/3) + (4/4) + (2/2) 10A/19A
HOXA11 - - (3/3) - (4/4) - (2/2) 10B/NS
ESR1 + + (4/4) + (3/4) + (2/2) 3A/11D
PGR - - (4/4) - (2/3) - (2/2) NS/12B
AR + (4/4) + (4/4) + (2/2) NS/NS
NS = Not shown.
Strat. Epi/ = Stratified epithelium.
* From Cunha et al. (2017).
Fig. 2. ESR1 immunostaining of a 13-week intact female fetal reproductive tract
(AC121) grown for 4 weeks in an untreated ovariectomized female athymic mouse host.
The epithelia of the uterine tube and vaginal plate (UGS-derived) are reactive for ESR1,
while endometrial/cervical epithelia are not (B). The red arrowhead marks the uterotubal
junction remarkable for the sharp transition in ESR1 staining. Detail of ESR1-negative
endometrial epithelium (C). Note that the inner layer of mesenchymal cells of the uterine
corpus (presumed endometrial stroma) is strongly ESR1-positive in contrast to periph-
eral mesenchyme (presumptive myometrium), which is weakly ESR1-positive. The
stroma of the uterine tube is also ESR1 reactive but to a far lesser degree than in the
corresponding area of uterine corpus.
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3.1.2.2. Progesterone receptor (PGR). PGR was not detected in either
epithelial or mesenchymal cells of all grafted organs (uterine tube,
uterine corpus, uterine cervix and vagina) grown in untreated
ovariectomized hosts (not illustrated, Tables 3–5), and thus
mimicked observations seen in non-grafted specimens in the
accompanying paper epithelium (Cunha et al., 2017).
3.1.3. Keratins (KRT)
3.1.3.1. Keratin 7 (KRT7) and Keratin 8 (KRT8). The staining pattern
was similar for KRT7 and KRT8 in human female reproductive tracts
that were non-grafted (Cunha et al., 2017) or grown in untreated
ovariectomized hosts (Fig. 3, Tables 3–5). Accordingly, KRT7 and
KRT8 were strongly expressed in the simple columnar epithelia of the
uterine tube, uterine corpus and uterine cervix, and weakly expressed
in epithelium of the vagina/vaginal plate (Fig. 3). In areas containing a
stratified epithelium interpreted as vagina/cervix, KRT7 and KRT8
were expressed in the apical but not the basal epithelial cells (Fig. 3C,
E & F).
3.1.3.2. Keratin 19 (KRT19). KRT19 was detected in epithelia of the
vaginal plate, vagina, cervix, uterine corpus and uterine tube in human
female reproductive tract xenografts grown in untreated
ovariectomized hosts (Fig. 4 and Tables 3–5). The pattern of KRT19
expression was virtually identical to that of non-grafted specimens of a
similar gestational age (Cunha et al., 2017). The distinguishing feature
for KRT19 versus KRT7/KRT8 was that in areas containing a stratified
epithelium (vagina/cervix) KRT19 was expressed throughout the full
epithelial thickness (basal to apical cells) (Fig. 4C-D).
3.1.3.3. Keratin 6 (KRT6). KRT6 is a keratin normally associated with
stratified epithelia and accordingly was only detected in the presumed
exocervix, vagina (Fig. 5A & C) and vaginal plate (Fig. 5D and Tables 3–
5). Simple columnar epithelia of the uterine tube (not illustrated),
uterine corpus, and endocervix did not express KRT6 (Fig. 5A &B). The
KRT6 staining pattern was similar in xenografts of human female
reproductive tracts grown in untreated ovariectomized hosts and in
non-grafted specimens of comparable age (Cunha et al., 2017).
3.1.3.4. Keratin 14 (KRT14). KRT14 is normally expressed in basal
and supra-basal cells of stratified epithelia (Moll et al., 1982, 2008). In
epithelium of the developing mouse Müllerian vagina, KRT14 is a
marker of maturing vaginal epithelium whose expression is preceded
by and dependent upon prior expression of ΔNp63 (Kurita and Cunha,
2001). In non-grafted human fetal female reproductive tracts, KRT14
was first detected in small patches of basal epithelial cells within the
vaginal plate at 14 weeks of gestation (see Fig. 5A-B, in Cunha et al.
(2017)). In xenografts of 13- and 14-week human fetal female
reproductive tracts grown in untreated hosts, KRT14 was likewise
detected in FOXA1-positive epithelium of the UGS-derived vaginal
plate (Robboy et al., 2017) (Fig. 6A-B and Tables 3–5). For PAX2-
positive Müllerian-derived vaginal epithelium (Robboy et al., 2017),
KRT14 was rarely detected (Fig. 6A & C). KRT14 was also not detected
in epithelia of the uterine tube, uterine corpus and the cervix (Fig. 6A)
Thus, the pattern of KRT14 expression in xenografts of human fetal
female reproductive tracts was nearly identical to that of non-grafted
specimens of a similar gestational age (Cunha et al., 2017).
3.1.3.5. Keratin 10 (KRT10). As expected, KRT10 was not expressed
in epithelia of grafts grown in untreated ovariectomized hosts (not
illustrated, Tables 3–5).
3.1.4. Epithelial transcription factors
3.1.4.1. TP63. The ΔNp63 isoform of TP63 is a vaginal epithelial
identity factor that is required for and specifies vaginal differentiation
of mouse Müllerian epithelium (Kurita and Cunha, 2001; Kurita et al.,
2005a). In non-grafted human fetal reproductive tracts all stratified
epithelia (vaginal plate, vagina and cervix) were strongly TP63-positive,
while the simple columnar epithelia of the uterine fundus and uterine
tube were negative for TP63 (Cunha et al., 2017). The pseudostratified
columnar epithelium at the presumed transition between the
Fig. 3. KRT8 (A-C) and KRT7 (D-F) immunostaining in an intact human fetal
reproductive tract grown for 4 weeks in an untreated ovariectomized female athymic
mouse host. The specimens come from 13-week (A-C & F [AC121]) and 14-week fetuses
(D-E [AC159]). In truly stratified epithelium (presumptive exocervix and vagina) the
basal epithelial cells (arrowheads) are unstained. KRT7 &KRT8 is expressed in single
layered epithelium or apical epithelial cells of multilayered epithelia. Vg. Plate=vaginal
plate.
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endocervix and lower uterine corpus exhibited patchy single cell
expression of TP63 in non-grafted specimens (Cunha et al., 2017).
Similarly, in xenografts of 11- to 14-week human fetal female
reproductive tracts grown in untreated hosts, TP63 was strongly
expressed in stratified epithelium of the vaginal plate and in epithelia
of the presumed exocervix and vagina (Fig. 7B, D-E and Tables 3–5).
Conversely, TP63 was not detected in the columnar epithelium of the
uterine tube (Fig. 7C), uterotubal junction (Fig. 7C & F) and upper
uterine corpus (uterine fundus) (Fig. 7C) in xenografts grown in
untreated ovariectomized hosts. A rapid decrease in the percent
TP63-reactive epithelial cells was seen at the transition from
stratified squamous to simple columnar epithelium at the presumed
exocervix/endocervix boundary (Fig. 7D-E). Areas presumed to be the
upper endocervix/lower uterine corpus boundary (Fig. 7A) exhibited
patchy single cell expression of TP63 in xenografts grown in untreated
hosts (Fig. 7A). The pattern of TP63 expression seen in the xenografts
was virtually identical to that of non-grafted specimens of comparable
gestational age (Cunha et al., 2017).
3.1.4.2. RUNX1. In mice, RUNX1 is essential for expression of ΔNp63
in cervicovaginal epithelial cells. Perinatal exposure to DES represses
RUNX1 expression that in turn prevents ΔNp63 expression in Müllerian
epithelium, which leads to cervicovaginal adenosis (Kurita et al., 2004;
Laronda et al., 2012, 2013). Given the mechanistic association of RUNX1
and ΔNp63, the pattern of expression of these two transcription factors is
fairly congruent in 14–16 week human female fetal reproductive tracts in
so far as both TP63 and RUNX1 were not detected in the columnar
epithelium of the uterine tube and uterotubal junction, but were strongly
expressed in the stratified epithelium of the vaginal plate and in
epithelium of the presumed vagina and exocervix, with patchy single
cell expression in epithelium of the lower uterine corpus/cervix (Cunha
et al., 2017). In grafts of 11- to 14-week human female fetal reproductive
tracts grown in untreated ovariectomized hosts, RUNX1 was expressed in
epithelia of the vaginal plate (Fig. 8B&F and Tables 3–5), vagina, uterine
cervix, the uterine corpus, but not in the uterine tube (Fig. 8D). At the
uterotubal junction RUNX1 immunostaining abruptly decreased from
scattered positive in uterine epithelium to negative in tubal epithelium
(Fig. 8E). RUNX1 was also detected in mesenchymal cells, especially in
association with stratified vaginal epithelium (Fig. 8B&F) and less so or
not at all in mesenchymal cells associated with the uterine corpus and
uterine tube (Fig. 8A, C-D). Thus, the pattern of Runx1 expression seen in
the xenografts was similar to that in non-grafted specimens of comparable
gestational age (Cunha et al., 2017)
3.1.5. Mesenchymal transcription factors
3.1.5.1. ISL1 and HOXA11. ISL1 is expressed in the nuclei of
mesenchymal cells in the lower portion of human fetal female
reproductive tract, namely in vaginal and cervical mesenchymal cells,
but not in mesenchymal cells of the uterus and uterine tube (Cunha
et al., 2017). In contrast, HOXA11 is expressed in mesenchymal cells of
Fig. 4. KRT19 immunostaining of an intact 13-week human fetal reproductive tract (AC121) grown for 4 weeks in an untreated ovariectomized female athymic mouse host. KRT19 was
detected in simple columnar epithelia of the uterine tube (E), uterine corpus (A-B), endocervix (not illustrated), as well as in stratified epithelia of the presumed exocervix, vagina and
vaginal plate (A, C &D) in basal through apical epithelial cells.
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the developing human uterine corpus, but not in mesenchyme of the
uterine tube, vagina and cervix (Cunha et al., 2017). This same pattern
of ISL1 and HOXA11 expression was seen in human female fetal
reproductive tracts grown for 4 weeks in untreated ovariectomized
hosts (Fig. 9 and Tables 3–5).
3.1.6. Summary
Protein expression was assessed by immunohistochemistry in 5
xenografted human female fetal reproductive tracts of 11–15 weeks of
gestation grown for an additional 4 weeks in vivo in untreated ovariecto-
mized hosts. The expression of sex steroid receptors, keratins, epithelial
and mesenchymal transcription factors was remarkably similar to that of
non-grafted specimens of comparable age (Cunha et al., 2017).
3.2. Epithelial and mesenchymal differentiation in grafts of human
fetal female reproductive tracts grown in DES-treated ovariectomized
female hosts
3.2.1. General
Many proteins in developing human fetal reproductive tracts grown
in DES-treated ovariectomized hosts exhibit an expression pattern like
that of comparable grafts grown in untreated ovariectomized hosts
(Tables 3–5). The figures presented below will emphasize patterns of
protein expression that differ in DES-treated versus untreated hosts.
3.2.2. Morphological effects of DES on human female reproductive
tract xenografts
Both non-grafted specimens and specimens grafted into untreated
ovariectomized hosts in the age range of 11–17 weeks showed few if
any endometrial/cervical glands. In contrast, DES stimulated endome-
trial and cervical gland formation (see Figs. 10, 11, 13 and 14) and
increased plication (folding) of tubal epithelium (Figs. 10, 13, 15 and
18). Two DES-treated specimen disclosed the presence of glandular
epithelium (adenosis) admixed with mature stratified squamous vagi-
nal epithelium (Figs. 10, 11, 13–15).
3.2.3. Sex steroid receptors
3.2.3.1. ESR1. DES had striking effects on ESR1 expression in
xenografts of human fetal reproductive tracts (Tables 3–5). DES-
treated tubal epithelium consisted of a mixture of ESR1-positive and
ESR1-negative cells (Fig. 10A), which contrasted with the
homogeneous ESR1 staining in (a) non-grafted specimens (Cunha
et al., 2017) and (b) tubal grafts grown in untreated ovariectomized
hosts (compare with Fig. 2A-B). Conversely, DES treatment (a)
induced prominent ESR1 expression in epithelium of the uterine
corpus and endocervix (Fig. 10B and Table 4) and (b) in glands of
these areas (Fig. 10C). The strong ESR1 expression in epithelium of
Fig. 5. KRT6 immunostaining of an intact 13-week human fetal reproductive tract (AC121) grown for 4 weeks in an untreated ovariectomized female athymic mouse host and
immunostained for KRT6. Stratified squamous epithelia of the presumed exocervix, vagina and vaginal plate (A, C & D) express KRT6 in basal through apical epithelial cells. Simple
columnar epithelia of the uterine tube (not illustrated), uterine corpus and presumed endocervix do not express KRT6 (A-B).
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the uterine corpus and endocervix of xenografts in DES-treated
hosts contrasted with the absence of ESR1 in (a) uterine and cervical
epithelium of non-grafted specimens (Cunha et al., 2017) and in (b)
specimens grown in untreated ovariectomized hosts (compare with
Fig. 2). Two DES-treated vaginal specimens exhibited both mature
vaginal epithelium and simple columnar adenotic epithelium, both
of which expressed ESR1 (Fig. 10D). ESR1 expression was
maintained in a substantial subset of mesenchymal cells in the
uterine tube, uterine corpus and uterine cervix at levels/intensities
similar to that seen in non-grafted specimens (Cunha et al., 2017)
and in specimens grown in untreated ovariectomized hosts (compare
with Fig. 2). Vaginal mesenchyme of DES-treated specimens
remained devoid of ESR1 or very weakly expressed (Fig. 10D), and
thus was similar to that seen in non-grafted specimens (Cunha et al.,
2017) and specimens grown in untreated ovariectomized hosts
(compare with Fig. 2A, inset).
3.2.3.2. PGR. PGR was rarely seen in epithelium and mesenchyme of
grafts of human fetal reproductive organs grown in untreated
ovariectomized hosts (Tables 3–5). In contrast, we found prominent
PGR immunostaining in epithelial and mesenchymal cells of the
uterine tube, uterine corpus, and cervix grown in DES-treated
ovariectomized hosts (Fig. 11A). Two vaginal xenografts grown in
DES-treated hosts exhibited mature vaginal epithelium as well as
adenosis, and both exhibited intense PGR immunostaining. In DES-
treated mature vaginal epithelium, PGR was confined to the basal and
the immediate supra-basal cells (Fig. 11B).
3.2.4. Keratins
3.2.4.1. Keratin 7 (KRT7) and Keratin 8 (KRT8). Expression of
KRT7 and KRT8 was detected in epithelia of all organs of the
developing human female fetal reproductive tract in xenografts
grown in DES-treated ovariectomized hosts even though staining
intensity appeared to be generally reduced relative to grafts grown in
untreated hosts (Fig. 12 and Tables 3–5). Indeed, in some cases
epithelial cells were completely devoid of KRT7 and KRT8 reactivity
with patchy expression (Fig. 12C-D). Mature vaginal epithelium was
mostly devoid of KRT8 staining in xenografts grown in DES-treated
hosts, while adenotic epithelium was KRT7- and KRT8-reactive
(Fig. 12B).
3.2.4.2. Keratin 19 (KRT19). KRT19 expression in xenografts of DES-
treated human female fetal reproductive tracts was virtually identical
(Fig. 13, Tables 3–5) to that seen in non-grafted specimens of
comparable gestational age (Cunha et al., 2017) and in comparably
aged specimens grown in untreated ovariectomized hosts (See Fig. 4).
Areas of mature vaginal epithelial differentiation and adenotic
Fig. 6. KRT14 immunostaining in an intact 13-week human fetal reproductive tract (AC121) grown for 4 weeks in an untreated ovariectomized female athymic mouse host. KRT14 was
detected only in epithelia of the vagina (A & C)/vaginal plate (A-B). The vaginal plate is FOXA1-positive and derived from UGS epithelium (Robboy et al., 2017), while the stratified
PAX2-positive Müllerian-derived vaginal epithelium (Robboy et al., 2017) (A & C) is mostly KRT14-negative. Stratified squamous epithelia of the presumed exocervix (A) as well as the
simple columnar epithelia of the endocervix, uterine corpus and uterine tube lack KRT14 reactivity (A).
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epithelium expressed KRT19 in xenografts grown in DES-treated hosts
(Fig. 13).
3.2.4.3. Keratin 6 (KRT6). KRT6 expression in xenografts grown in
DES-treated hosts exhibited a pattern similar to that seen in xenografts
grown in untreated ovariectomized hosts and non-grafted specimens of
comparable gestational age (Cunha et al., 2017). In this regard, KRT6
was observed throughout the full epithelial thickness in stratified
vaginal epithelium (Fig. 14 and Tables 3–5). In addition, patchy
expression of KRT6 was seen in epithelial cells of the uterine corpus
(arrowheads in Fig. 14A). Adenotic epithelium was devoid of KRT6
staining (Fig. 14B).
3.2.4.4. Keratin 14 (KRT14). KRT14 expression in grafts of human
female fetal reproductive tracts grown in DES-treated ovariectomized
hosts exhibited a pattern similar to that seen in xenografts grown in
untreated ovariectomized hosts and non-grafted specimens of
comparable gestational age (Cunha et al., 2017) in so far as KRT14
was observed in basal cells of mature stratified vagina epithelium
(Fig. 15A-B and Tables 3–5). In contrast, simple columnar adenotic
epithelium was devoid of KRT14 staining in xenografts grown in DES-
treated hosts (Fig. 15B).
3.2.4.5. Keratin 10 (KRT10). KRT10 was not expressed in any of the
organs of the human fetal reproductive tract, including the mature
stratified vagina epithelium (Tables 3–5 not illustrated).
3.2.5. Epithelial transcription factors
3.2.5.1. TP63. TP63 expression was similar in grafts of human female
fetal reproductive tracts grown in (a) DES-treated ovariectomized
hosts, (b) in untreated ovariectomized hosts and (c) in non-grafted
specimens of comparable gestational age (Cunha et al., 2017) in so far
as TP63 was observed in basal and suprabasal cells of stratified
Fig. 7. TP63 immunostaining of an intact 13-week human fetal reproductive tract (AC121) grown for 4 weeks in an untreated ovariectomized female athymic mouse host. TP63 was
strongly expressed in the stratified epithelium of the vaginal plate (D), vagina (B &D), but not in the simple columnar epithelia of the uterine tube (C), uterotubal junction (F) and upper
uterine corpus. Transitions between stratified and simple columnar epithelium (D-E) exhibited a sharp reduction in TP63 to patchy single cell expression, which was also seen in the
presumed endocervical region (A).
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epithelia in the vagina and cervix (Fig. 16A-C and Tables 3–5). In
contrast, adenotic epithelium was devoid of TP63 staining (Fig. 16C).
Epithelium of the uterine tube and upper uterine corpus (Fig. 16A)
remained non-reactive for TP63, in contrast to patchy TP63 expression
in epithelium of the lower uterine corpus/cervix of xenografts grown in
DES-treated hosts (Fig. 16D).
3.2.5.2. RUNX1. The RUNX1 staining pattern was similar in (a)
xenografts grown in DES-treated ovariectomized hosts, (b) untreated
ovariectomized hosts and (c) non-grafted specimens of comparable
gestational age (Cunha et al., 2017) with a few exceptions. Uterine
epithelium and endometrial glands were devoid of RUNX1 staining in
xenografts grown in DES-treated hosts (Fig. 17A & C and Tables 3–5),
which contrasted with the presence of RUNX1 in non-grafted
specimens of comparable gestational age (Cunha et al., 2017) and in
xenografts grown in untreated ovariectomized hosts (compare with
Fig. 8). RUNX1 was expressed in the endocervical region (Fig. 17A)
and in mature vaginal epithelium, but not in vaginal adenosis and in
uterine tubal epithelium (Fig. 17A-B).
3.2.6. Mesenchymal transcription factors
3.2.6.1. ISL1 and HOXA11. The expression of ISL1 and HOXA11 did
not differ from that seen in non-grafted specimens (Cunha et al., 2017)
or in xenografts of untreated or DES-treated ovariectomized hosts.
Following DES-treatment HOXA11 was expressed in mesenchymal
cells of the uterine corpus and cervix (Fig. 18B and Tables 3–5). ISL1
was expressed in mesenchymal cells associated with vaginal
epithelium, whether stratified squamous or glandular (adenosis)
(Fig. 18A).
3.2.7. α–ACT2
α-ACT2 is a marker of smooth muscle differentiation. Smooth muscle
forms a significant portion of the fibromuscular wall of organs of the
female reproductive tract, especially in the uterine corpus/endocervix.
For both the uterine corpus and the uterine tube, the epithelium is
surrounded by a layer of fibroblastic stromal cells (called endometrial
stroma in the uterus). This stromal layer in both the uterine corpus and
the uterine tube is in turn surrounded by a smooth muscle layer, which in
the uterus is called the myometrium. This pattern (epithelium, stroma
and smooth muscle) revealed by αACT2 staining is consistently seen in
non-grafted tubal specimens (Cunha et al., 2017) as well as in grafts of
human fetal tube grown in untreated ovariectomized hosts (Fig. 19A,
Tables 3–5). However, in human fetal uterine tube grown in DES-treated
ovariectomized hosts, the αACT2-positive smooth muscle layer was in
intimate association with the epithelium and the αACT2-negative
mesenchymal layer was absent (Fig. 19B).
Fig. 8. RUNX1 immunostaining in an intact 13-week human fetal reproductive tract
(AC121) grown for 4 weeks in an untreated ovariectomized female athymic mouse host
and immunostained for RUNX1. RUNX1 was strongly expressed in the stratified
epithelium of the vaginal plate (B & F), vagina (B & F), and also in the simple columnar
epithelia of the presumed endocervix (B-C) and the uterine corpus (A &D). RUNX1
expression diminished to undetectable at the uterotubal junction (E) and was not
expressed in epithelium of the uterine tube (D).
Fig. 9. ISL1 (A) and HOXA11 (B) immunostaining in an intact 13-week human fetal
reproductive tract (AC121) grown for 4 weeks in an untreated ovariectomized female
athymic mouse host. ISL1 is expressed in the mesenchyme associated with the vaginal
plate and vagina, whereas HOXA11 is expressed in the mesenchyme associated with the
uterine corpus.
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4. Discussion
The xenograft model we pioneered three decades ago has resulted
in a broad array of findings and better understanding of how the
human male and female internal and external genitalia develop
normally and how drug administration can perturb normal develop-
ment (Cunha et al., 1987b, 1987a, 1988; Robboy et al., 1982;
Sugimura et al., 1988; Taguchi et al., 1983, 1984; Yonemura et al.,
1995; Baskin et al., 1997; Isaacson et al., 2017). This xenograft
model is a fully ethical method for in vivo testing of endocrine
disruptors on human fetal reproductive tracts. Our earlier xenograft
studies were carried out before technical advances in molecular
biology and immunohistochemistry were available to explore the
molecular mechanisms involved in human female reproductive tract
development. With modern methods, we have re-visited this model,
have analyzed/confirmed our earlier H & E observations and ex-
tended our understanding through analysis of epithelial and me-
senchymal protein differentiation markers (Cunha et al., 2017;
Robboy et al., 2017). Accordingly, we have demonstrated that
epithelial morphology and differentiation markers are remarkably
similar in xenografts grown in untreated female hosts to those seen in
non-grafted specimens of comparable age (Robboy et al., 2017;
Cunha et al., 2017) even though the hormonal conditions provided
by the untreated ovariectomized hosts are considerably different
from in utero hormonal conditions. In preparation for our studies, we
debated whether to use ovary-intact hosts or ovariectomized hosts.
We chose the latter so that the effect of DES could be attributed to
DES only.
Previously we showed that human female reproductive tract devel-
opment proceeds normally in grafts grown in untreated female hosts
(Cunha et al., 1987a; Robboy et al., 1982; Taguchi et al., 1983). In
contrast, human fetal female reproductive tracts grown in DES-treated
Fig. 10. ESR1 immunostaining in an intact 13-week human fetal reproductive tract (AC122) grown for 4 weeks in a DES-treated ovariectomized female athymic mouse host. Tubal
epithelium (A) expresses ESR1 but at a level reduced relative to non-grafted and specimens grafted into untreated hosts. ESR1 expression in the uterine tube, glands of the uterine
corpus and cervix (B) (low magnification), (C) (high magnification) of uterine glands. In the vaginal region ESR1 reactivity is seen in both mature squamous epithelium and adenosis,
while the mesenchyme is largely unreactive (D).
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female hosts exhibited: (a) partial obliteration of the upper genital
tract, (b) inhibition of differentiation of utero-tubal mesenchyme into
stromal and smooth muscle layers, (c) alteration of plical development
in the Fallopian (uterine) tube, (d) inhibition of normal transformation
of caudal Müllerian epithelium into a stratified squamous vaginal
epithelium (VgE) and (e) induction of vaginal adenosis (Robboy
et al., 1982; Taguchi et al., 1983; Robboy, 1983).
Previously we induced adenosis in human female fetal xenografts
grown in DES-treated hosts (Robboy et al., 1982; Taguchi et al., 1983).
Similarly, adenosis was observed in two of four 14-week xenografts
treated with DES. Clinical experience has shown that not all women
exposed in utero to DES develop adenosis. In fact, the frequency of
vaginal epithelial changes (VEC) and adenosis in DES daughters
exposed during the critical window is about 34% (O'Brien et al.,
1979) and 15% (Robboy et al., 1979), respectively. VEC changes are
a broader definition of vaginal abnormality reflecting cases where the
adenosis may have partially healed and only the metaplastic squamous
epithelium remains.
In the present study DES elicited multiple effects on epithelial
morphology as well as protein differentiation markers in xenografts of
human female fetal reproductive tracts. DES induced precocious gland
formation in the uterine corpus and cervix. Glands are rudimentary
shallow outpouchings at 14–16 weeks of gestation in non-grafted
specimens (Cunha et al., 2017; Robboy et al., 2017), and gland
development is minimal in xenografts grown for 4 weeks in untreated
ovariectomized hosts. Human uterine/cervical gland development
appears to be stimulated by estrogen. Three observations support this
belief: (a) Uterine/cervical glands are absent early in the second
trimester before elevation of endogenous estrogens. (b) At 21 weeks
uterine/cervical glands are elongated and branched within the endo-
metrial stroma in non-grafted specimens when effects of endogenous
estrogens can be readily recognized in vaginal epithelium (Robboy
et al., 2017). (c) DES-treated xenografts of comparable age (~ 14 + 4
weeks) exhibited considerable gland development. Thus, uterine/
cervical gland development correlates with elevated endogenous estro-
gen or exogenously administered estrogen. These data starkly contrast
with the initial appearance of uterine glands in the mice which occurs
at ~ 7 days postnatal when endogenous estrogen levels are exceedingly
low (Pang et al., 1979) and serum levels of alpha-fetoprotein are high
(Adinolfi et al., 1990). Alpha-fetoprotein binds steroidal estrogens at
high affinity (Savu et al., 1981) and thus “neutralizes” serum estrogen.
Moreover, analysis of neonatal ESR1 null mice indicates that initial
appearance of uterine glands is independent of ESR1 (Nanjappa et al.,
2015). Thus, uterine/cervical gland development is stimulated by DES
(and perhaps endogenous estrogens) in humans, while uterine gland
formation in mice is estrogen independent.
ESR1 is undetectable in epithelium of the human fetal uterine
corpus during the second trimester (Cunha et al., 2017), but was
induced by DES treatment in xenografts. Estrogen is known to up-
regulate ESR1 mRNA and protein (Read et al., 1989; Saceda et al.,
1988) presumably via binding of liganded ESR1 to estrogen-response
elements associated with the gene encoding ESR1 (Liu et al., 2003).
However, human uterine epithelium appears completely ESR1-nega-
tive in untreated hosts but is strongly expressed following DES
treatment. Hence, it is unclear if DES up-regulates the expression of
ESR1 in immature uterine epithelium of human directly via epithelial
ESR1 as shown in human breast and endometrial cell lines or via
paracrine mechanisms.
The striking DES induction of ESR1 in epithelial cells of the human
fetal uterine corpus raises two possibilities: (a) ESR1 may be present in
epithelium of the human fetal uterine corpus at levels below the
sensitivity of IHC, and thus DES-induction of uterine epithelial ESR1
may be mediated directly via epithelial ESR1. (b) Alternatively ESR1
may be induced in human fetal uterine epithelium via a paracrine
mechanism mediated by ESR1 abundantly expressed in adjacent
mesenchymal cells (see Fig. 10 in Cunha et al. (2017)). Such paracrine
regulation of sex steroid receptors in mice (androgen receptor, ESR1
and PGR) is well documented (Cunha et al., 1980; Kurita et al., 1998,
2000a, 2000b).
PGR regulation differs vastly in mice and humans. Many studies
have shown that human PGR is directly induced by estrogen, a concept
verified in both cell lines and in many tissues (Janne et al., 1975;
Horwitz and McGuire, 1979). Direct estrogen-induced expression of
PGR is furthermore affirmed through analysis of tissue recombinants
composed of ESR1-deficient αERKO uterine stroma plus adult human
uterine epithelium (Kurita et al., 2005b). In contrast, in adult mice
uterine epithelial PGR is strongly expressed in untreated ovariecto-
mized mice and disappears completely following estrogen administra-
Fig. 11. PGR immunostaining in an intact 13-week human fetal reproductive tract
(AC122) grown for 4 weeks in a DES-treated ovariectomized female athymic mouse host.
PGR is expressed strongly in epithelial and inner mesenchymal cells of the female
reproductive tract (A). In vagina, PGR is expressed principally in the basal/suprabasal
cells and in the adenosis (B).
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Fig. 12. KRT7 immunostaining in a 13-week human fetal reproductive tract (AC122) grown for 4 weeks in a DES-treated ovariectomized female athymic mouse host. KRT7 expression
is reduced in endometrial glands (C) and uterine tube (D), but prominent in vaginal adenosis (B).
Fig. 13. KRT19 immunostaining in an intact 13-week human fetal reproductive tract (AC122) grown for 4 weeks in a DES-treated ovariectomized female athymic mouse host. KRT19 is
expressed in adenosis, other glandular epithelia, and in the suprabasal cells in the vaginal squamous epithelium (B).
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tion; this regulation of epithelial PGR is mediated via mesenchymal
ESR1 (Kurita et al., 2000b). Thus, uterine epithelial PGR regulation
differs radically in mice versus humans. The initial expression of
uterine epithelial PGR during development also differs in mice versus
humans. In mice PGR initially appears at 3 days postnatal in uterine
epithelium (Kurita et al., 2001). It is unlikely that this initial PGR
expression in mice is estrogen induced since estrogen levels are
exceedingly low at this stage and alpha-fetoprotein levels are high as
discussed above. In the human fetal uterus PGR is (a) not expressed in
the epithelium at 14–18 weeks (before evidence of estrogen action), (b)
is more broadly expressed at 21 weeks when evidence of estrogen
action is apparent (Cunha et al., 2017), (c) is rarely seen in epithelium
and mesenchyme of grafts of human fetal reproductive organs grown in
untreated ovariectomized hosts, and (d) is globally induced by DES,
thus suggesting that during human fetal development the initial
appearance of human epithelial and mesenchymal PGR is estrogen
induced.
DES induction of proliferation and differentiation of human fetal
vaginal epithelium deserves special comment. In humans ESR1 is
undetectable in vaginal plate epithelium at 12 weeks, but is expressed
in small patches in the vaginal plate/vaginal epithelium at 14–18
weeks. The surrounding vaginal mesenchymal cells were devoid of
ESR1 at this stage (Cunha et al., 2017). Subsequently at 21 weeks,
when the vaginal epithelium had differentiated into a thick mature
epithelium, basal and suprabasal vaginal epithelial cells prominently
expressed ESR1, and in adulthood estrogen receptors are present in
both vaginal epithelial and stromal cells (Gould et al., 1983). In
newborn mice ESR1 appears in epithelial cells at about 2 days
postnatal (Kurita et al., 2001). In adulthood, estrogen receptors are
present in both vaginal epithelium and stroma in mice (Stumpf and
Sar, 1976). Thus, the common feature in both mice and humans is
the initial absence of ESR1 in vaginal epithelium, followed later by
ESR1 expression in vaginal epithelium. The ontogeny of ESR1
expression in vaginal mesenchyme differs in humans and mice.
During vaginal development in newborn mice, ESR1 is abundantly
expressed throughout vaginal mesenchyme (Kurita et al., 2001).
Conversely, during human vaginal development ESR1 is initially
expressed at 8–14 weeks in a minority of mesenchymal cells
associated with the vaginal plate, but only becomes prominent in
vaginal mesenchyme at 21 weeks by which time the vaginal epithe-
lium has proliferated into a multi-layer mature epithelium presum-
ably in response to endogenous estrogen (Cunha et al., 2017). The
significance of these species differences in the ontogeny of mesench-
ymal ESR1 remains to be determined.
In response to estrogen, vaginal epithelium of both mice and
humans proliferates to form a multi-layered epithelium that undergoes
stratified squamous differentiation. In mice the response of vaginal
epithelium to estrogenic stimulation involves two separate events: (a)
estrogen-induced epithelial proliferation to generate a multi-layered
epithelium and (b) stratified squamous differentiation and expression
of proteins (KRT14, TP63, KRT10) characteristic of stratified squa-
mous vaginal epithelium. Through analysis of mouse vaginal tissue
recombinants composed of epithelium and mesenchyme derived from
wild-type mice and ESR1 null mice, we showed that estrogen-induced
vaginal epithelial proliferation is mediated indirectly through stromal
ESR1 (paracrine mechanism), while epithelial ESR1 was required for
estrogen-induced vaginal epithelial cornification and expression of
keratin 10 (direct mechanism) (Buchanan et al., 1998). Thus, in mice
both mesenchymal and epithelial ESR1 are required to achieve the
complete vaginal epithelial response to estrogen. Whether similar
mechanisms of vaginal epithelial differentiation occur in humans
remain to be determined. Curiously, at 21 weeks ESR1-positive
mesenchymal cells were rarely seen near the vaginal introitus, while
a high percentage of vaginal mesenchymal cells were ESR1-positive
near the vaginal/cervical boundary (Cunha et al., 2017). These two
radically different distributions of ESR1-positive vaginal mesenchymal
cells in cranial versus caudal zones within the developing human
vagina may be indicative of substantially different mechanisms of
vaginal epithelial response to estrogen in these two areas. Regardless,
substantial mouse/human differences are apparent regarding the
ontogeny of vaginal ESR1 and response to estrogen. Additional speci-
mens and further research will be required to understand these
differences.
Major DES-induced changes in keratin expression were seen in
vaginal epithelium. As a result of DES treatment two vaginal epithelial
histo-types formed: (a) mature thick stratified squamous vaginal
epithelial differentiation and (b) adenosis (retained simple columnar
epithelium associated with the mature vaginal epithelium). These two
histo-types presumably emerged from epithelium of the vaginal plate
whose Müllerian/urogenital sinus composition changes with gesta-
tional age (Robboy et al., 2017). Differentiation of a multi-layered
mature glycogenated squamous vaginal epithelium represents the
Fig. 14. KRT6 immunostaining in an intact 13-week human fetal reproductive tract
(AC122) grown for 4 weeks in a DES-treated ovariectomized female athymic mouse host.
The vaginal squamous epithelial cells were highly reactive, while adenosis was not (B).
The glandular epithelial cells of the cervix, uterine corpus and uterine tube were non-
reactive except for small patches (A, arrowheads).
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Fig. 15. KRT14 immunostaining in an intact 13-week human fetal reproductive tract (AC122) grown for 4 weeks in a DES-treated ovariectomized female athymic mouse host. KRT14 is
reactive in the basal epithelial cells of the vagina (A-B), but not in adenosis (B), nor epithelium of the cervix, uterine corpus and uterine tube (A).
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Fig. 16. TP63 immunostaining in an intact 13- and 14-week human fetal reproductive tract grown for 4 weeks in a DES-treated ovariectomized female athymic mouse host. TP63
immunostaining (AC159) is absent in the uterine tube and uterine corpus (A, [AC159]). Early and maturing squamous epithelia in the cervix (B, [AC159]) and mature vaginal epithelium
are TP63-positive but not adenotic epithelium in the vagina (C, [AC122]). Foci of epithelium in the region of the endocervix/uterine corpus (D, [AC159]) exhibit patchy TP63 expression
(arrowheads).
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Fig. 17. RUNX1 immunostaining in an intact 13-week human fetal reproductive tract (AC122) grown for 4 weeks in a DES-treated ovariectomized female athymic mouse host. Mature
vaginal epithelium (A-B) expresses TP63, but not adenotic epithelium (B). RUNX1 was not detected in the uterine tube, uterine corpus (A) and uterine glands (C).
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typical response to estrogen. In contrast, adenosis occurs frequently in
DES daughters (O'Brien et al., 1979; Robboy et al., 1979) and rarely in
the un-exposed human population (Herbst et al., 1975a). From studies
in mice, DES-induced adenosis involves the failure of the simple
columnar Müllerian epithelium to transform into a stratified squamous
epithelium, and in mice the resultant adenotic epithelium expresses a
spectrum of differentiation markers indicative of uterine epithelium
(Kurita et al., 2004; Kurita, 2011). The adenotic human epithelium
induced by DES expresses ESR1, PGR, KRT7, KRT8, KRT19, but not
TP63, RUNX1 and KRT14, a pattern of differentiation marker expres-
sion consistent with uterine epithelial differentiation (Cunha et al.,
2017; Laronda et al., 2013; Terakawa et al., 2016).
DES had a striking effect on differentiation of mesenchyme of the
uterine tube, which normally forms an αACT2-negative layer in
intimate association with the epithelium, which is in turn surrounded
by an αACT2-positive smooth muscle layer. This pattern is seen in non-
grafted specimens and in specimens grown in untreated ovariecto-
mized hosts. In DES-treated specimens the αACT2-positive smooth
muscle layer is in direct association with the epithelium and the
αACT2-negative mesenchymal layer is absent. This effect is presumed
to be mediated by ESR1 expressed in the tubal mesenchyme (see
Fig. 12F in Cunha et al. (2017)). This observation corresponds to our
earlier observation of inhibition of differentiation of utero-tubal
mesenchyme into stromal and smooth muscle layers (Robboy et al.,
1982) that in part may be the basis of the tubal malformations
described in DES daughters as discussed above.
Our observation of abnormal smooth muscle differentiation in the
uterine tube, as well as the many other DES-induced alterations in
morphogenesis and molecular expression, provide a wealth of bio-end
points of estrogen-induced malformation/alteration of the human
female reproductive tract. These bio-endpoints can be used in the
future for testing of environmental estrogenic endocrine disruptors
such as bisphenol-A and its analogues directly on developing human
organs, thus addressing concerns of relevance/applicability of animal
models to human teratogenesis.
Fig. 18. ISL1 (A) and HOXA11 immunostaining (B) in an intact 13-week human fetal
reproductive tract (AC122) grown for 4 weeks in a DES-treated ovariectomized female
athymic mouse host. ISL1-reactive mesenchyme (A) surrounds vaginal squamous/
transitional epithelium. The adenotic epithelium is unreactive. The mesenchyme of the
endometrial stroma is highly and diffusely HOXA11 reactive (B).
Fig. 19. αACT2 immunostaining of 13-week human uterine tubes grown for 4 weeks in (A, [AC121]) an untreated ovariectomized host and (B, [AC122]) in a DES-treated
ovariectomized host stained for αACT2. Note that in the control (A), a substantial mesenchymal layer encompasses the tubal epithelium, which DES treatment (B) has obliterated,
resulting in a misplaced αACT2 smooth muscle layer, which now comes into a intimate association with the epithelium.
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